Vismodegib

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

Retrieved on: 
Monday, February 13, 2023
GSK, TIGIT, CD96, Vismodegib, Biomedical sciences, Therapy, Berkeley, Cancer, Drug development, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., CD226, University, Antibody, SAN, AstraZeneca, BS, Doctor of Philosophy, Pharmaceutical industry, Nursing, Iris, PVRIG, GSK plc, Genetics

NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO).

Key Points: 
  • NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO).
  • Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully advancing the development of multiple investigational therapies in oncology.
  • “I am incredibly pleased to welcome Iris to Zentalis, rounding out our management team with a seasoned leader who has extensive experience in oncology drug development,” said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.
  • Prior to GSK, Dr. Roth served in senior leadership roles at various biopharmaceutical companies, including as Chief Operating Officer of Kartos Therapeutics, and Vice President, Global Medicine Leader of AstraZeneca.

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

Retrieved on: 
Wednesday, January 4, 2023
Hoffmann-La Roche, IMS Health, Boehringer Ingelheim, Head, Genentech, University of London, Squamous cell carcinoma, RP1, RP2, Health, GSK, Skin, CSCC, RP3, University, Imperial College London, Center for Study of Science, Technology and Policy (CSTEP), Nursing, BCC, Marketing, Molecular biology, Management, Fine chemical, Sanofi, Biotechnology, Science, Medicine, Vismodegib, Biosimilar

“These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.

Key Points: 
  • “These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1,” said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • “Chris led the launch of Libtayo in cutaneous squamous cell carcinoma (CSCC) at Sanofi, and was also involved with the launch of Erivedge in basal cell carcinoma (BCC) when at Genentech.
  • Sush will partner with Chris on our go-to-market strategy in the U.S. with RP1 and also in defining our commercialization strategy for the rest of the world.
  • Chris began his career with GSK where he held several sales and marketing leadership roles of increasing responsibility.

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Retrieved on: 
Monday, December 12, 2022
Squamous cell carcinoma, FLT3, Lymphatic system, Dana–Farber Cancer Institute, Venetoclax, Cancer, Disease, BTK, Patient, COVID-19, AML, MDS, Patent, Risk, Form 10-K, Azacitidine, B-cell lymphoma, MYD88, Myelodysplastic syndrome, Multimedia, Toxic leukoencephalopathy, NCI, Security (finance), Toll-like receptor, Webcast, Food, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Roche, U2AF1, Form, Marketing, Mutation, Therapy, IL-1R, CRS, Biomarker, Research, CRADA, FDA, BCC, Safety, Hoffmann-La Roche, Acute myeloid leukemia, NF, TLR, Pharmaceutical industry, SF3B1, Curie Institute (Paris), Vismodegib, IRAK4

LEXINGTON, Mass., Dec. 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1a dose escalation study of emavusertib (CA-4948), a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (hrMDS) in both targeted and non-targeted populations. Patients in a targeted population are those with disease harboring U2AF1, SF3B1 (collectively "spliceosome") or FLT3 mutations. The company also announced positive initial data of emavusertib in combination with venetoclax in patients with AML or hrMDS that enrolled in the combination phase (Phase 1b) of the TakeAim Leukemia study prior to the partial clinical hold placed in April 2022.

Key Points: 
  • This represents 11 additional patients treated in targeted monotherapy populations and 13 additional patients in the non-targeted monotherapy population.
  • In addition to the monotherapy data, there are 4 patients with AML/hrMDS who have been treated with emavusertib in combination with venetoclax.
  • Previous data presented by Curis highlighted preliminary efficacy data of emavusertib in R/R AML/MDS patients whose disease is characterized by spliceosome or FLT3 mutation.
  • TakeAim Leukemia Study (NCT04278768) - This study is only enrolling in the monotherapy dose finding phase (phase 1a) of the study.

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Retrieved on: 
Tuesday, December 6, 2022
FLT3, Therapy, Lymphatic system, SF3B1, Dana–Farber Cancer Institute, Hematology, Webcast, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Azacitidine, Society, Patient, Cancer, B-cell lymphoma, Genentech, Roche, U2AF1, FDA, BTK, Vismodegib, Myelodysplastic syndrome, Multimedia, IRAK4, Hoffmann-La Roche, Acute myeloid leukemia, Mobile phone, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.

Key Points: 
  • ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.
  • This presentation will include data for 28 additional evaluable AML/MDS patients:
    Patients in a targeted population are those with FLT3, U2AF1, or SF3B1 mutations.
  • A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com .
  • A replay of the webcast will be available on the Curis website shortly after completion of the call.

Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

Retrieved on: 
Wednesday, November 2, 2022
Genentech, Azacitidine, B-cell lymphoma, IRAK4, Cancer, Lymphatic system, Roche, Vismodegib, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BTK, NASDAQ, Company, FDA, Patient, Acute myeloid leukemia, Food, Multimedia, Therapy, Myelodysplastic syndrome, Hoffmann-La Roche, Pharmaceutical industry, Curie Institute (Paris)

Management will host a conference call on the same day at 4:30 p.m.

Key Points: 
  • Management will host a conference call on the same day at 4:30 p.m.
  • To access the live conference call, please dial (888) 346-6389 fromthe United Statesor (412) 317-5252 from other locations, shortly before4:30 p.m.
  • The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section.
  • A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Curis Announces Date for the 2nd Annual VISTA Symposium

Retrieved on: 
Tuesday, September 20, 2022
BTK, Therapy, Curie Institute (Paris), Roche, IRAK4, Lymphatic system, Hoffmann-La Roche, FDA, Food, MDS, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Vismodegib, B-cell lymphoma, AML, Multimedia, Genentech, Azacitidine, Orphan, Pharmaceutical industry

LEXINGTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the 2nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET.

Key Points: 
  • To learn more about the symposium and register to attend, please visit https://bit.ly/VISTA22 .
  • Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.
  • Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge for the treatment of advanced basal cell carcinoma.

Curis to Present at Upcoming Healthcare Conferences in September

Retrieved on: 
Wednesday, September 7, 2022
Patient, Lymphatic system, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, IRAK4, AML, Hoffmann-La Roche, Genentech, Food, Orphan, Leukemia, B-cell lymphoma, Azacitidine, Multimedia, Roche, Conference, Company, FDA, Therapy, Vismodegib, Investor, Webcast, BTK, MDS, Pharmaceutical industry, Online shopping, Curie Institute (Paris)

Mr. Dentzer will also participate in a Leukemia and MDS panel at the Cantor Oncology and HemOnc Conference on Wednesday, September 28, 2022 at 3:25 p.m.

Key Points: 
  • Mr. Dentzer will also participate in a Leukemia and MDS panel at the Cantor Oncology and HemOnc Conference on Wednesday, September 28, 2022 at 3:25 p.m.
  • A replay of the webcast will be available on the Curis website for approximately 90 days following the event.
  • Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

Retrieved on: 
Thursday, July 28, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Genentech, Vismodegib, Food, IRAK4, Hoffmann-La Roche, Myelodysplastic syndrome, NASDAQ, Cancer, Roche, FDA, Company, Patient, Lymphatic system, BTK, Therapy, Acute myeloid leukemia, B-cell lymphoma, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., July 28, 2022 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.

Key Points: 
  • LEXINGTON, Mass., July 28, 2022 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.
  • To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET.
  • The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section.
  • A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Curis to Present at 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
IRAK4, Hoffmann-La Roche, Company, Conference, Genentech, Food, Webcast, Roche, Investor, Vismodegib, Therapy, Multimedia, B-cell lymphoma, FDA, Patient, Acute myeloid leukemia, Myelodysplastic syndrome, BTK, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphatic system, Cancer, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., June 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m. in New York, NY.

Key Points: 
  • LEXINGTON, Mass., June 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m. in New York, NY.
  • A replay of the webcast will be available on the Curis website for 90 days following the event.
  • Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.
  • In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

Retrieved on: 
Thursday, May 12, 2022
Acute myeloid leukemia, Risk, BTK, Form, Toxic epidermal necrolysis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Hoffmann-La Roche, BCC, Multimedia, Patient, Form 10-K, NCI, COVID-19, Lymphatic system, Marketing, B-cell lymphoma, Research, Patent, FDA, Intention, Time, Lists of disasters, Roche, Forward-looking statement, Genentech, Safety, Biomarker, IRAK4, Therapy, Private Securities Litigation Reform Act, CRADA, SEC, Cancer, Myelodysplastic syndrome, Security (finance), Pharmaceutical industry, Curie Institute (Paris), Vismodegib

LEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress (EHA), which will be held virtually and in-person in Vienna on June 9-12, 2022. The abstracts include data from both the TakeAim Leukemia and TakeAim Lymphoma studies as well as other studies by Curis and independent collaborators. These planned presentations are in addition to the previously announced presentations scheduled for the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022.

Key Points: 
  • In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.
  • Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge for the treatment of advanced basal cell carcinoma.
  • Cautionary Note Regarding Forward-Looking Statements:
    This press release contains forward-looking statements within the meaning of the U.S.
  • Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings.